Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

Buy-and-Bill

COVID-19

Case-Based Roundtable

Chronic Hand Eczema

Chronic Spontaneous Urticaria 

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Spot Test

Editorial Advisory Board

Partners

Subscribe

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

Articles

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Daily Derm Times: August 1, 2025

Marie Bosslett is the assistant editor of 

 and joined the MJH Life Sciences team in October 2024. She attended Loyola University Maryland in Baltimore and earned a Bachelor of Arts in Communication with minors in marketing and writing. When she’s not writing, Marie enjoys going to concerts, reading on the beach, and spending time with friends and family.

Dendy Engelman, MD, FACMS, FAAD, explores the latest advancements in laser and energy-based dermatological treatments, including skin resurfacing and body contouring.

The Latest Trends in Laser and Energy-Based Dermatology

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and received her Masters in Digital Media from Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family. 

Kolansky identifies oxybenzone and fragrances as leading causes of sunscreen allergies.

Common Sunscreen Allergens: What to Watch For

Whitney Hovenic, MD's new SPOOGE sunscreen hopes to engage Gen Z in sun protection, merging skincare with fun and effective sun care strategies.

SPOOGE by Whitney Hovenic, MD, Aims to Bridge the Sunscreen Adherence Gap in a Unique Way

Dermatology Times connects dermatology professionals with key skin disorder coverage, therapeutic strategies, clinical trial updates, and expert insights.

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times - Dermatology News and Clinical Insights

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

clinical

Clinical

In this episode of The Cutaneous Connection, Bradley Burnam, the founder and CEO of 

, discusses his journey in the pharmaceutical landscape: from his battle with an aggressive antimicrobial resistant infection to the beginnings of Turn, and to the current state of 

Like this podcast, have suggestions, or want to participate in future episodes? Contact our team at 

Turn Therapeutics' Bradley Burnam recently spoke with Dermatology Times.

PODCAST: From Infection to Innovation - The Turn Therapeutics Story

The aesthetics industry saw a massive boom during the COVID-19 pandemic for both invasive and non-invasive procedures. Amir Karam, M.D., San Diego, Calif., reveals what caused this increase in demand for aesthetics procedures and discusses the outlook for the future of the industry. 

The Cutaneous Connection- Episode 13: The COVID-19 Cosmetic Surgery Boom

Daily Derm Times: July 31, 2025

Daily Derm Times: July 30, 2025

Deepti Gupta, MD, emphasized SPD's focus on delivering practical clinical insights, highlighting emerging research, and fostering meaningful professional connections

SPD 2025: Bridging Research and Clinical Care

Renata Block, DMSc, MMS, PA-C, interviews Adam Friedman, MD, FAAD, about his research into cannabidiol’s photoprotective potential, clinical trial design, and future directions.

Derm Dispatch: Adam Friedman, MD, FAAD, Unpacks the Science Behind CBD’s Role in UV Protection

, host Renata Block, DMSc, MMS, PA-C, sat down with Adam Friedman, MD, FAAD, professor and chair of dermatology at the George Washington University School of Medicine and Health Sciences, to discuss his decades-long journey researching cannabidiol (CBD) and its potential in photoprotection.

The conversation offered a look at the origin story of a topical CBD formulation backed by clinical evidence and how it might one day change the way dermatology clinicians think about sun protection.

"I think we have got to take a step back even further in terms of, 'How do I even get into this space?'" Friedman said. "It’s often by accident."

Friedman’s interest in cannabinoids was sparked by a former resident, Liz Robinson, MD, who shared her research on synthetic cannabinoids in dermatomyositis. While topical delivery was a challenge due to CBD’s lipophilic nature, it was that very difficulty that intrigued him.

"If you tell me I can’t deliver it, I want to deliver it more than anything," Friedman said.

With a background in nanotechnology drug development, Friedman had the tools to take on that challenge. The 2018 Farm Bill opened new research pathways by legalizing CBD with less than 0.3% THC, allowing him to move forward with work that was previously stalled due to regulatory constraints.

The idea to study CBD’s role in photoprotection came unexpectedly. A Mexico-based company, Mino Labs, producing high-purity CBD, approached Friedman and his longtime mentor, Brian Berman, MD, PhD, with a goal: validate their ingredient’s efficacy through real science, not marketing hype.

Polypodium leucotomos supplements like Heliocare helped shape the study’s direction. Friedman noted that while early studies were solid, copycat products diluted credibility in the space. 

"Unless you do the work, you cannot piggyback on someone else’s investment of time and genius and energy," he warned. "I think consumers need to be aware of that."

Unlike most CBD research stuck in preclinical models, Friedman’s study involved an IRB-approved clinical trial with 18 subjects. It tested a nanoparticle-encapsulated CBD cream using a split-site model in which patients served as their own controls.

Participants applied either vehicle cream or active cream to protected skin areas twice daily for 2 weeks, followed by UVA exposure. The team then analyzed biopsies for visible inflammation, epidermal thickening, and DNA-level changes, particularly a UVA-induced mitochondrial mutation called "the common deletion."

Journal of the American Academy of Dermatology

, and the topical formulation is now available commercially under the brand ClementineMD.

Still, Friedman emphasized that it is not a sunscreen substitute: "My hope is that people look at this as sunscreen’s best friend. No sunscreen is 100% perfect. It doesn't mean no sunscreen is necessary; it means we need to have a little bit of a backup plan, and that's kind of the point of this."

Commercialization and Regulatory Roadblocks

Despite the promising data and product launch, Friedman acknowledged the uphill battle in getting CBD products to consumers due to regulatory gray zones.

"Even though technically this is legal...a lot of the major outlets through which you would push your products didn’t want anything to do with it," he explained.
"We are undermining a space that could be so impactful from a medical perspective and hindering research and science."

Major retailers and social media platforms still place restrictions on cannabinoid marketing, limiting visibility and scale. Compared to Canada, where regulations are more relaxed, the US remains "very behind," he said.

Friedman hopes this successful entry into cosmeceuticals will build momentum toward prescription drug development, particularly in cutaneous lupus, where topical treatment options are virtually nonexistent.

"There is no FDA-approved topical lupus treatment," Friedman said. "Our work in anandamide is focusing on cutaneous lupus... and we’ve shown in a mouse model that we could treat it topically."

The team is now collaborating with Penn dermatologists through an NIH-funded SBIR grant to further pursue this avenue.

While the CBD product’s road to market has been long—over 20 years since Friedman first developed the core nanotechnology as a third-year medical student—he says the greatest reward is seeing it come to life.

"The most exciting piece of this is knowing that people are applying something on their skin that I invented," he said.

Videos

Lauren Madigan, MD, shares vital insights on complex dermatology, emphasizing accurate diagnoses and the importance of diversity in dermatologic imagery.

Unraveling Complex Dermatology, Challenging Diagnoses, and the Power of Visuals

, Lauren Madigan, MD, associate professor of dermatology at the University of Utah, shared key insights from 3 of her educational sessions focused on complex medical dermatology, inpatient consults, and image-based case studies.

In her session “Complex Medical Dermatology: Top Diagnoses You Can’t Afford to Miss,” which she presented alongside 

, Madigan emphasized the critical importance of carefully evaluating pruritus.

 She presented cases where underlying malignancies were the root cause of generalized itching, diagnoses that may have been missed without thorough workup. She also stressed the need for clinicians to critically reassess presumed diagnoses. For instance, a case initially believed to be a flare of bullous pemphigoid was actually shingles. Her key message: Always question if the clinical picture aligns with the diagnosis, especially when symptoms evolve unexpectedly.

“If it doesn't make sense, don't hesitate to go back and rethink and re-question and re-evaluate the patients. Make sure you get them the right diagnosis,” she advised.

From her presentation “Interesting Cases from Inpatient Consults,” Madigan highlighted the diagnostic challenges of neutrophilic dermatoses.

She discussed the importance of recognizing severe forms, such as necrotizing neutrophilic dermatosis, which require urgent intervention. She also presented a case of VEXAS syndrome, an emerging diagnosis driven by clonal mutations causing neutrophilic skin inflammation. Equally vital was her caution against overdiagnosis, using a case of sporotrichosis misidentified as pyoderma gangrenosum to illustrate the value of biopsy and culture in preventing mismanagement.

“Underdiagnosis can lead to morbidity but so can overdiagnosis,” Madigan told attendees, “[We’re] wanting to make sure that we're recognizing these patients in the best way we can.”

In the “Kodachrome Case Studies” session, Madigan drew from her editorial experience with the 

Journal of the American Medical Association

 She reinforced the diagnostic power of morphology in classic presentations, while also warning about visual disease mimics. Additionally, she underscored the importance of diversity and representation in dermatologic imagery across skin tones and in emerging or rare diseases, citing Mpox as a prime example where widely shared images improved diagnostic accuracy.

Beyond the conference, Madigan is engaged in collaborative inpatient dermatology research, particularly around drug eruptions and complex infections. She also studies adult cutaneous mastocytosis, aiming to refine staging and treatment with targeted therapies like KIT D816V inhibitors to improve outcomes and quality of life for patients.

“I'm always excited to be participating in those types of trials or those types of investigations for our patients with complex drug eruptions or complex infections or just demonstrating the value of what we add to the hospital,” Madigan told 

1. Madigan L, Patel A. Complex Medical Dermatology: Top Diagnoses You Can’t Afford to Miss. Presented at: 2025 Elevate-Derm Summer Conference; July 24-28; Park City, UT.

2. Madigan, L. Interesting Cases from Inpatient Consults. Presented at: 2025 Elevate-Derm Summer Conference; July 24-28; Park City, UT.

3. Madigan, L. Kodachrome Case Studies. Presented at: 2025 Elevate-Derm Summer Conference; July 24-28; Park City, UT.

Lauren Madigan, MD, highlighted critical insights at the Elevate-Derm Summer 2025 conference, focusing on complex medical dermatology, inpatient consults, and image-based case studies. She emphasized the importance of thorough evaluation in pruritus cases to avoid misdiagnosis, using examples like shingles mistaken for bullous pemphigoid. Madigan also discussed the challenges of diagnosing neutrophilic dermatoses and the risks of overdiagnosis. Her session on case studies underscored the diagnostic power of morphology and the need for diverse dermatologic imagery. Madigan is actively involved in research on drug eruptions and cutaneous mastocytosis.

Discover key insights on melanonychia and the transformative role of AI in dermatopathology from Ata Moshiri, MD, MPH, FAAD, at Elevate-Derm Summer 2025.

Ata Moshiri, MD, MPH, FAAD, on Melanonychia Biopsy Cues and AI's Role in Dermatopathology 

, Ata Moshiri, MD, MPH, FAAD, assistant professor of dermatology and dermatopathology at NYU Langone and Director of Laboratory Operations and the Dermatopathology Fellowship, offered essential clinical insights into his session on melanonychia. In a conversation with 

, he also shared some exciting artificial intelligence (AI) research.

In his talk, "Melanonychia: When to Biopsy & How to Decide," Moshiri emphasized that while longitudinal melanonychia (dark pigmented bands running along the nail) often raises concern for nail melanoma, most cases are benign.

However, identifying worrisome features is crucial. Key indicators that a biopsy may be necessary include new-onset melanonychia in older individuals, especially if limited to a single digit, most notably the thumb or big toe. Additional red flags are bands wider than three millimeters, triangular or irregular shapes, pigmentation extending into the nail folds (known as Hutchinson's sign), and any associated nail plate dystrophy.

“If there's any doubt, any new longitudinal melanonychia in an older individual in a single digit probably needs to be biopsied,” Moshiri stressed. “That's the biggest takeaway of all of it.”

He also clarified that biopsies should target the nail matrix, not the nail plate or bed, as that’s where melanoma originates. Missing the correct tissue can lead to misdiagnosis.

Beyond clinical pearls, Moshiri shared insights into his ongoing research at NYU, where he is part of an innovative AI research group. Their focus is on developing algorithms capable of predicting melanoma behavior based on histologic features, specifically, which lesions are more likely to metastasize or respond to immunotherapy.

 By leveraging AI’s capacity to detect subtle patterns invisible to the human eye, the team hopes to enhance diagnostic precision and patient outcomes. Overall, Moshiri views AI as a transformative force in dermatopathology over the next 5 to 10 years.

“It's a very exciting time to be doing this kind of research in medicine,” he said, noting that the advancements being made today may soon become routine practice. With both a sharp eye for clinical detail and a forward-thinking approach to innovation, Moshiri’s work underscores the evolving future of dermatologic care.

1. Moshiri, A. Melanonychia: When to Biopsy & How to Decide. Presented at: 2025 Elevate-Derm Summer Conference; July 24-28; Park City, UT.

2. Johannet P, Coudray N, Donnelly DM, et al. Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma. 

. 2021;27(1):131-140. doi:10.1158/1078-0432.CCR-20-2415

At the Elevate-Derm Summer 2025 Conference, Dr. Ata Moshiri highlighted the importance of discerning when to biopsy longitudinal melanonychia, emphasizing that most cases are benign but certain features warrant further investigation. Key indicators for biopsy include new-onset melanonychia in older individuals, especially in a single digit, and specific characteristics like band width and shape. Moshiri also discussed his AI research at NYU, focusing on algorithms to predict melanoma behavior, aiming to improve diagnostic accuracy and patient outcomes. He views AI as a transformative tool in dermatopathology.

Discover key insights on melanonychia and the transformative potential of artificial intelligence from Ata Moshiri, MD, MPH, FAAD, at Elevate-Derm Summer 2025.

Earlier this summer, in an historic step for global dermatology, the World Health Assembly (WHA) passed its first-ever resolution on skin disease, recognizing skin health as a global public health priority.

 spoke with Claire Fuller, MA, FRCP, a consultant dermatologist and chair of the International Foundation for Dermatology (IFD), to understand the implications of the landmark resolution and the urgent work still needed to advance access, equity, and innovation in skin health worldwide.

"This is an absolute game changer for skin health worldwide," Fuller said. "It gives us a visa, if you will, to be able to go and talk to our member states' ministers of health to say, 'Look, you've signed up to this. How can we help you deliver it?'"

A new WHA resolution spotlights skin health, pushing member states to close care gaps and integrate dermatology into public health.

Claire Fuller, MA, FRCP: WHA Resolution on Skin Diseases Marks a Global Turning Point for Dermatologic Health

Dermatology’s Representation in the WHO

While skin conditions remain among the most common diseases globally,

dermatology has historically lacked formal representation at the World Health Organization (WHO). Fuller explained that until now, no WHO department, unit, or dedicated officer focused on dermatology or skin disease.

"There is no dermatology department, no dermatologist, no emphasis or unit within the World Health Organization that considers dermatology," Fuller noted. Instead, the only consistent dermatologic voice at the WHO has been through the International League of Dermatological Societies (ILDS), which is the sole non-state actor in official relations with WHO focused on skin disease.

For the past 2 decades, the ILDS and its humanitarian arm, the IFD, have worked to raise the profile of skin health across WHO departments, including neglected tropical diseases, essential medicines, noncommunicable diseases, and even climate change.

"We do have a real opportunity as non-state actors in official relations to be able to raise issues of skin health at the WHO level, but without much of a mandate," she added.

Adopted in May, the new WHA resolution marks the first formal recognition of skin diseases in the organization’s 78-year history. The resolution calls on member states, global stakeholders, and the WHO itself to elevate skin health within their public health strategies.

Integrating skin care into primary health systems

Reducing stigma associated with skin conditions

Expanding training and credentialing for frontline health care workers

Building dermatologic leadership at the national level

"Priority steps would be to encourage member states... to draft or develop a national policy for common skin disease," Fuller said. "That framework might include a recommendation to circulate learning materials that are already available, making sure that they are accessible to their frontline health care workers."

She emphasized the need for education programs that embed dermatology into primary care training and ensure health workers are both credentialed and motivated to diagnose and manage common skin conditions.

Addressing Global Access and Workforce Gaps

The resolution also sheds light on disparities in dermatologic care. Fuller cited countries where access is virtually nonexistent.

"In the Solomon Islands, a population of around 900,000, there are currently no dermatologists. In Papua New Guinea, a population of 11 million, there are 2 dermatologists. In the Gambia, there are 24 million people and no dermatologists," she said.

Even in wealthier nations with many dermatologists, distribution is uneven. "There are islands of urban concentration, but rural areas effectively have no access," she noted, referencing stark geographic gaps in the US and Brazil.

To combat this, Fuller urges countries to identify national dermatology leaders and invest in regional training.

Now that the resolution is passed, Fuller emphasized that the hard work begins: coordination, policy-making, and implementation at the country level.

"[Leaders] can come together and coordinate action around the areas that they've been commanded to do in the resolution," she said. That includes advocacy, leadership development, integration of care, stigma reduction, and curriculum building.

Member states adopt landmark resolution on skin diseases at 78th World Health Assembly. News release. GlobalSkin. May 24, 2025. Accessed July 21, 2025. 

https://globalskin.org/component/content/article/78-gs-2019-content/649-member-states-adopt-landmark-resolution-on-skin-diseases-at-78th-world-health-assembly?Itemid=1710

Seth D, Cheldize K, Brown D, Freeman EF. Global burden of skin disease: inequities and innovations. 

General Dermatology

Latest News